Verbascoside has been isolated form L. speciosa after several different chromatographic methods. After its purification, the structure has been unequivocally established using modern spectroscopic techniques. As for the antiviral activity, the maximum non toxic concentration has been established and this concentration has been used in the anti herpes assay, in vitro. Mechanism of action for this molecule regarding the anti-herpes activity has been studied encompassing the following assays: virucidal activity, cellular receptor assay, penetration assay and intracellular assay, in order to understand the activity for this natural product.
Plants of the genus Lepechinia (Lamiaceae family) are used in traditional medicine for the treatment of uterine infections [1a] , uterine tumors [1b], gastrointestinal ailments [1c] and diabetes mellitus control [1d,2] . In addition, vasorelaxant [3a] spasmolytic [3b,3c] , antimicrobial [1a,4a] , cytotoxic [bb] and antioxidant [5] activities have been also reported. In this work, the antiviral activity of a compound isolated from Lepechinia speciosa was analysed. The focus was on herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections. HSV-1 is widespread in the human population and commonly causes infections of the skin or mucosal surfaces, principally associated with oral diseases and occasionally it can cause serious diseases such as encephalitis and ocular infections. HSV-2 is commonly associated to sexually transmitted diseases, being the main cause of genital ulceration worldwide causing severe infections in neonates and immunocompromised patients and it is a cofactor in human immunodeficiency virus type 1 (HIV-1) transmission. The drug of choice for treating these diseases is acyclovir [6] , but the widely use for the treatment and suppressive therapy of herpes simplex virus infections led to the appearance of acyclovirresistant strains as a result of long-term therapy [7] . Therefore, new strategies should be developed as alternative therapy. In this study, we showed the antiviral activity of a verbascoside (Figure 1 ) isolated from Lepechinia speciosa against herpes simplex virus types 1 and 2 with results obtained for in vitro analysis.
There are several pharmacological properties already described for verbascoside, such as vasorelaxant [8a] NPC Natural Product Communications It was observed that verbascoside exhibit a dose dependent activity and EC 50 values were 58 μg/mL to HSV-1 and 8.9 μg/mL to HSV-2. The selective index (SI) of the verbascoside was higher than 3.4 and 22.4 to HSV-1 and HSV-2, respectively (Table 1) . It was not possible to determine the exact CC 50 values of verbascoside and acyclovir, once the higher concentration used was 200 μg/mL. In contrast of aciclovir, whose activity is only observed in one stage of viral cycle, verbascoside was capable to act in different stages of both viruses replication.
In order to determine the mechanism of action of verbascoside against HSV-1 and HSV-2 infections, experiments were performed to evaluate their inhibitory effect at different stages of virus infection into cells. As observed in Figure 2 , verbascoside acted in different stages when comparing both viruses. Against HSV-1, it showed virucidal action, demonstrating that one of the mechanisms of action was the ability to interact with the viral particles and to prevent the viral adsorption. In this step, verbascoside was able to inactivate the HSV-1 particles at 82.2%. Inhibitory activity was also observed in intracellular step showing 82.2% of viral inhibition. Against HSV-2, verbascoside interacted with cellular receptors avoiding 92% the virus attachment and also inhibiting 92% the penetration step. These results are important due to the fact that the onset of viral infection is an attractive target for therapy because the virus can be blocked before establishing the infection. It should be noticed that the verbascoside mechanism of action was different against HSV-1and HSV-2, showing specific activity. This molecule has previously been isolated in our group from another medicinal plant and non-toxic effects have been shown using different methodologies [9a,9b] . 
Conclusion:
Despite acyclovir is the drug of choice for treating the HSV infections, new antiviral agents exhibiting different mechanisms of action are urgently needed, mainly due to the high number of acyclovir-resistant strains. Verbascoside showed to be a very versatile and potent compound against HSV-1 and 2, being capable to inhibit different steps of viral replication differently from acyclovir.
Experimental
Cells and Virus: Vero cells (African green monkey kidney) were grown in Eagle's minimum essential medium (MEM) supplemented with 2 mM L-glutamine, 50 μg/mL gentamicin, 2.5 μg/mL fungizone and 10% heat-inactivated fetal bovine serum (FBS) and maintained at 37°C in 5% CO 2 atmosphere. Herpes simplex virus type 1 and type 2 strains isolated from typical oral and genital lesions, respectively, at the Departamento de Virologia, Universidade Federal do Rio de Janeiro (UFRJ), Brazil. The isolates were typed by polymerase chain reaction (PCR) using specific primers to identify HSV-1 and HSV-2 [10] and propagated in a Vero cell culture. The titres were assessed by the cytopathic The dried and powdered aerial parts of L. speciosa were extracted with ethanol at room temperature for at least 24 h, and this was repeated until exhaustion of the material. The ethanol extract was concentrated under reduced pressure, suspended in water and then submitted to a liquid-liquid partition procedure with different solvents [11] . The ethyl acetate (FAE) fraction (1.4 g) was fractionated over a silica gel column starting with dichloromethane and increasing proportions of methanol. Fraction 28, eluted with EtOAc: MeOH (6:1) yielded 212 mg of verbascoside (15.14% w/w).
Cytotoxicity assay
Verbascoside from aerial parts of L. speciosa and acyclovir were dissolved in dimethyl sulfoxide (DMSO). Stock solutions were prepared in water at 400 μg/mL and sterilized by filtration using a 0.22 μm Millipore membrane filter. The cytotoxicity assay was performed by incubating triplicate Vero cell monolayers cultivated in 96-well microplates with two-fold serial dilutions of compounds for 48 h at 37°C in 5% CO 2 atmosphere. The morphological alterations of the treated cells were observed in an inverted optical microscope (Leitz) and the maximum non-toxic concentrations (MNTC) were determined [12a] . Cellular viability was further evaluated by the neutral red dye-uptake method [12b] . The 50% cytotoxic concentration (CC 50 ) was defined as the compound concentration which caused a 50% reduction in the number of viable cells.
Antiviral activity assay:
Vero cell monolayers cultivated in 96-well microtitrer plates were treated with verbascoside or acyclovir at the MNTC (200μg/mL). Immediately after treatment, logarithmical dilutions of HSV-1 or HSV-2 suspensions were added to treated and untreated cell cultures. After 48 h incubation at 37°C in 5% CO 2 atmosphere, the virus titres in treated and untreated cells were determined. 
Mechanism of action studies
Virucidal assay: 100 μl of HSV-1 or HSV-2 suspension were added to either 900 μl of verbascoside, at concentration of 200μg/mL in MEM-Eagle, or MEM-Eagle without serum (control), according to Chen et al. [12d] . The samples were incubated at 37°C for 2 h, diluted, and then inoculated in Vero cell monolayers. After 48 h incubation as before, the residual titres of the treated and untreated viruses were determined and expressed as percentage inhibition (PI).
Cellular receptor assay:
Verbascoside was added to Vero cell monolayers before infection (pretreatment) in order to evaluate the effect of the compounds on cell receptors. Vero cell monolayer was pretreated with verbascoside, at concentration of 200μg/mL, for 1 h at 4°C. After this time, the cells were washed three times with MEM-Eagle for removing sample, and the treated and untreated cells were inoculated with 100 TCID 50 /mL of HSV-1 or HSV-2. After incubating the cells at 37°C for 48 h, the supernatant was collected and virus titres in treated and untreated cells were determined and the activity was expressed as PI.
Penetration assay: Vero cell monolayers were inoculated with 100 TCID 50 /mL of HSV-1 or HSV-2 and incubated for 1 h at 4°C. After this period, the monolayers were washed with culture medium and verbascoside, at concentration of 200μg/mL, was added. The cultures were immediately shifted to 37°C to allow the penetration of the particles into the cells for another hour. After incubation, the monolayer was washed, MEM-Eagle was added, and the cultures incubated at 37°C for 48 h. After incubating, the supernatant was collected and virus titres in treated and untreated cells were determined and the activity was expressed as PI.
Intracellular assay: Vero cell monolayers were inoculated with 100 TCID 50 /mL of HSV-1 or HSV-2 and incubated at 37°C for two hours. The cells were washed and verbascoside at concentration of 200μg/mL or MEM-Eagle (control) were added and the cultures incubated at 37°C for 16 h. After incubation, the cells were washed to remove the compound before the release of viral particles. MEMEagle was added and the cultures incubated for 32 h at 37°C. After incubating, the supernatant was collected and virus titres in treated and untreated cells were determined and the activity was expressed as PI.
